Compositions and methods for detecting cancer

1. A method for treating cancer in a subject, comprising

a) obtaining a biological sample from the subject and applying said biological sample to a sialoglycan-microarray, said sialoglycan-microarray comprising at least four sialoglycan pairs, each of said at least four sialoglycan pairs differing only in the sialic acid residue present, wherein a first sialoglycan from each pair comprises Neu5Ac and a second sialoglycan from each pair comprises Neu5Gc, and wherein four sialoglycans of said at least 4 sialoglycan pairs comprise:

i) N-glycolylneuraminic acid-alpha2-6-N-acetylgalactosamine-alpha-R (Neu5Gcα2-6GalNAcα-R),

ii) Neu5Gc9Acα2-3Galβ1-4GlcNAcα-R,

iii) Neu5Gcα2-6Lacβ-R, and

iv) Neu5Gcα2-3Galβ1-3GalNAcβ-R,

b) determining, in said biological sample, the level of one or more antibody, wherein said one or more antibody binds to at least one sialoglycan selected from the group consisting of:

i) (Neu5Gcα2-6GalNAcα-R,

ii) Neu5Gc9Acα2-3Galβ1-4GlcNAcα-R,

iii) Neu5Gcα2-6Lacβ-R, and

iv) Neu5Gcα2-3Galβ1-3GalNAcβ-R,

c) comparing the level of said one or more antibody determined in step b) with the level of one or more antibody a control normal sample, wherein said one or more antibody in a control normal sample has the same binding specificity as said one or more antibody determined in step b),

d) identifying said subject as having cancer when the level of said one or more antibody detected in step b) is higher relative to the level of said one or more antibody in a control normal sample, and

e) initiating anti-cancer therapy in said subject identified as having cancer according to step d).

2. The method of claim 1 , wherein said subject is a mammal.

3. The method of claim 2 , wherein said subject is a human.

4. The method of claim 3 , wherein said biological sample is selected from the group consisting of serum, saliva, cerebrospinal fluid (CSF) and tissue extract.

5. The method of claim 4 , wherein said cancer comprises cancer of the prostate, ovary, lung, colon, pancreas, endometrium, parathyroid, thyroid, skin, breast or oropharynx.

6. The method of claim 1 , wherein the sialoglycans on said sialoglycan-microarray comprise a non-reducing end linker group conjugated to a substrate.

7. The method of claim 6 , wherein said substrate is selected from the group consisting of human serum albumin (HSA), a slide, a bead and an array.

8. The method of claim 1 , comprising an additional step prior to step e), wherein said additional step comprises selecting said subject identified as having cancer according to step d) for initiation of anti-cancer therapy.

9. The method of claim 1 , comprising an additional step prior to step e), wherein said additional step comprises selecting said subject identified as having cancer according to step d) for confirmatory diagnostic cancer testing.

10. The method of claim 1 , further comprising performing a confirmatory diagnostic cancer test in a subject identified as having cancer according to step d).

11. The method of claim 1 , wherein the one or more antibody detected in step b) has an area under the curve (AUC) for a Receiver Operator Characteristic (ROC) curve of cancer of greater than 0.50.

12. The method of claim 1 , wherein said identifying according to step d) comprises a cancer specificity greater than 50% as calculated by the equation: specificity=number of true negatives/(number of true negatives+number of false positives).

13. The method of claim 1 , wherein said identifying according to step d) comprises a cancer sensitivity greater than 50% as calculated by the equation: sensitivity=number of true positives/(number of true positives+number of false negatives).